Zenas BioPharma, Inc. (ZBIO)
About Zenas BioPharma, Inc.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $10.0M
- Net income
- -$377.7M
- Total assets
- $383.6M
- Market cap
- $1.1B
- Operating margin
- -3277.8%
- Net margin
- -3139.8%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $5.0M
- Operating expenses
- $168.9M
- Operating income
- -$163.9M
- Income tax
- $429.0K
- Net income
- -$157.0M
- EPS (basic)
- $-11.89
- EPS (diluted)
- $-11.89
Balance sheet
- Total assets
- $370.0M
- Current assets
- $355.9M
- Total liabilities
- $57.5M
- Current liabilities
- $57.3M
- Shareholders’ equity
- $312.5M
Cash flow
- Operating cash flow
- -$119.7M
- Investing cash flow
- -$30.6M
- Financing cash flow
- $413.0M
- Net cash flow
- $262.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.1B
- EPS (diluted)
- $-11.89
- Dividend yield
- 0.03%
- Shares outstanding
- 36.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 13, 2024
Zenas BioPharma, Inc. (ZBIO) Stock Price
- Reported a net loss of $377.7M in FY2025.
- Trading 30% below its 52-week high.
- Pays a dividend yielding about 0.03% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Zenas BioPharma, Inc..
Write a review
News about Zenas BioPharma, Inc.
News & sentiment via Polygon.io
Zenas BioPharma, Inc.: frequently asked questions
Is Zenas BioPharma, Inc. an American company?
Zenas BioPharma, Inc. is a US-based company headquartered in Waltham, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Zenas BioPharma, Inc. headquartered?
Zenas BioPharma, Inc. is headquartered in Waltham, Massachusetts, United States.
Is Zenas BioPharma, Inc. publicly traded?
Yes — Zenas BioPharma, Inc. is a publicly traded company. Its stock trades under the ticker symbol ZBIO on the NASDAQ.
What does Zenas BioPharma, Inc. do?
Zenas BioPharma, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
